Skip to main content
Quest Diagnostics

What’s Next on the Drug Abuse Landscape: Development of Laboratory Testing for Novel Psychoactive Substances (NPS)

PainWEEK 2023

Las Vegas, NV, Sep 5-8, 2023

Poster presentation: What’s Next on the Drug Abuse Landscape: Development of Laboratory Testing for Novel Psychoactive Substances (NPS)

Authors: Gudin J, Neifeld J, Solano R, Kain J, Bartock SH

Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
Drug Monitoring in Behavioral Health and During Times of Crisis
Audio Podcast
Phosphatidylethanol (PEth) blood test - Now available from Quest Diagnostics
Audio Podcast
Pharmacogenomics in Mental Health and Addiction
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Test FAQ
Drug Monitoring Antidepressants With Confirmation Urine and Serum
Test FAQ
Drug monitoring, Phoshatidylethanol (PEth), Blood Test
On-Demand Webinar
Drug Monitoring Webinar: Contributing Factors into the Skyrocketing Drug Misuse Epidemic in the US
Publication
Evaluation of alcohol markers in urine and oral fluid after regular and hard kombucha consumption

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.